NCT02596984View on ClinicalTrials.gov

Evaluation of the Pharmacokinetics of Caspofungin in ICU Patients

NACompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

March 16, 2015

Primary Completion Date

May 31, 2018

Study Completion Date

May 31, 2018

Conditions

Shock

Interventions

DRUG

Caspofungin

Either preemptive, empirical or curative prescription of Caspofungin by one of the ICUs' attending physician. Caspofungin will be administered according to the international recommendation

Trial Locations (3)

42000

CHU de SAINT-ETIENNE, Saint-Etienne

63000

CHU de CLERMONT-FERRAND, Clermont-Ferrand

75010

Hôpital Saint-Louis, Paris

All Listed Sponsors

collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

Centre Hospitalier Universitaire de Saint Etienne

OTHER

NCT02596984 - Evaluation of the Pharmacokinetics of Caspofungin in ICU Patients | Biotech Hunter | Biotech Hunter